News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Highlighting indications approved through extrapolation and manufacturing information in drug labels are attempts to raise doubts over the safety of biosimilars, according to Sandoz.
Pfizer pays $150m for Bamboo Therapeutics, and post-merger Shire terminates a Baxalta haemophilia programme. Welcome to Biopharma-Reporter’s gene therapy focus.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.